Japanese firm adds ex-Norvartis and Alnylam in-house counsel

Former in-house counsel at major pharma companies brings expertise in IP strategy, regulatory compliance, and business development across pharma and biotech.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Careers

Clarivate’s new IP president to ‘usher in next phase of growth’

9 June 2026 The data and intelligence firm appoints the former CEO of CPA Global—which Clarivate bought in 2020—to lead the IP division’s growth, as the global company aims to accelerate AI integration and streamline its core business operations.

Careers

Ex-Kirkland patent litigator jumps to rival firm

8 June 2026 Known for his work on major pharmaceutical patent disputes and landmark SEP cases, the London-based litigator has joined a new firm as partner.

Careers

Dehns appoints head of litigation following wave of senior hires

4 June 2026 The new recruit, who will also support the firm’s UPC practice, brings more than 25 years’ experience and a “strong track record of handling technically and legally complex disputes” in the UK.

More features

‘When a UPC judge wears their robe, they have no gender’

Hikma v Amarin: Six takeaways from the pivotal ruling

Clarivate’s new IP president to ‘usher in next phase of growth’

Fed Circ rejects Nexus’ appeal in generics row with biopharma firm

Ex-Kirkland patent litigator jumps to rival firm

Hikma triumphs at SCOTUS in landmark skinny-label ruling

Pfizer strikes $10.5 billion oncology deal with Chinese biotech

Dehns appoints head of litigation following wave of senior hires

Japanese firm adds ex-Norvartis and Alnylam in-house counsel

More on this story

Editor's picks

Editor's picks

More features